Skip to content
Companies

Mitera Biosciences

Placental protein therapy for transplant rejection

Raised to date

$1.1M

of $3M offered across 1 Form D filing

Still open
$1.9M
Investors
2
Last filed
May 6, 2026

About

Mitera Biosciences is an early-stage biotechnology company in Bellevue, Washington developing immunosuppressive therapeutics for autoimmune disease and organ transplant rejection. Its approach is built on a natural human protein produced by the placenta during pregnancy and expressed in the thymus, with intellectual property exclusively licensed from Cedars-Sinai Medical Center. The mechanism targets three arms of the immune response: impairing effector T cells, expanding regulatory T cells, and downregulating B cell function. The company emerged from stealth with $1.75 million in funding and is led by co-founder, president and CEO Kevin Chow, previously co-founder and CEO of Vitaeris, which was acquired by CSL Behring.

Borrows the immune-tolerance mechanism that lets a pregnancy avoid rejection, aiming for immunosuppression without the neurologic and kidney toxicity of calcineurin inhibitors that drives non-adherence in most kidney transplant patients.

Funding

  • Security to be acquiredFiled May 6, 2026Form D
    $1.1M/ $3M

Product

Placental protein immunotherapy program

Preclinical biologic therapeutic

An early-stage drug program derived from a natural human protein produced by the placenta during pregnancy and expressed in the thymus, developed as an immunosuppressive therapeutic for solid organ transplant rejection and autoimmune disorders.

  • Based on a naturally occurring human placental protein
  • Impairs effector T cells
  • Promotes proliferation of regulatory T cells

Built for

Solid organ transplant recipients, including kidney transplant patients with chronic antibody-mediated rejection, and patients with autoimmune disorders.

People on file